Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights
November 08, 2023 08:00 ET
|
Nuvectis Pharma, Inc.
Phase 1b Study of NXP800 in Patients with Platinum Resistant, ARID1a-Mutated Ovarian Carcinoma is Ongoing Initiated the Phase 1a Dose Escalation Study of NXP900 in Patients with Advanced Solid...
Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer
October 24, 2023 08:00 ET
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation
September 25, 2023 19:30 ET
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900
September 21, 2023 08:00 ET
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial
September 12, 2023 08:00 ET
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900
September 06, 2023 08:00 ET
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
September 01, 2023 08:00 ET
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma
August 17, 2023 08:00 ET
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma, Inc. Reports Second Quarter 2023 Financial Results and Business Highlights
August 09, 2023 08:00 ET
|
Nuvectis Pharma, Inc.
The Phase 1b study of NXP800 in patients with platinum resistant, ARID1a-mutated ovarian carcinoma is ongoingNXP900 IND cleared by the US FDA, start of Phase 1a study expected in Q3 2023 ...
Nuvectis Pharma Set to Join the Russell 2000® and Russell 3000® Indexes
June 20, 2023 08:00 ET
|
Nuvectis Pharma, Inc.
Fort Lee, NJ , June 20, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...